PORTRAZZA

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Ireland, Japan, Lithuania, Poland, Singapore.

Active ingredients

The drug PORTRAZZA contains one active pharmaceutical ingredient (API):

1	Necitumumab UNII 2BT4C47RUI - NECITUMUMAB
	Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donors.
	Read more about Human normal immunoglobulin G

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Portrazza Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FE03	Necitumumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
Discover more medicines within L01FE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1711639
JP	医薬品医療機器総合機構	4291448A1026
LT	Valstybinė vaistų kontrolės tarnyba	1079701
PL	Rejestru Produktów Leczniczych	100366940
SG	Health Sciences Authority	15292P
US	FDA, National Drug Code	0002-7716